Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
A phase 1/2 trial of Fulvestrant in advanced solid tumours, run by Phoenix Molecular Designs, active and no longer recruiting.
Overview
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT04115306 by Phoenix Molecular Designs, with 61 participants enrolled, started 2019-11-14 and due to reach its primary completion in 2026-12. Interventions recorded: PMD-026 and fulvestrant.
Similar pages
not linked directly; found by shared links- TrialPhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSNV4818 in Participants With Advanced Solid Tumors
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialCapivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialCFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.